receiver operator characteristics roc analysis (Genovis Inc)
Genovis Inc is a verified supplier 
Genovis Inc manufactures this product 
93
Structured Review
Genovis Inc
receiver operator characteristics roc analysis
Receiver Operator Characteristics Roc Analysis, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 93/100, based on 92 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/receiver+operator+characteristics+roc+analysis/OpeRATOR+Lyophilized/pmc12672138-17-54-54
Average 93 stars, based on 92 article reviews
Receiver Operator Characteristics Roc Analysis, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 93/100, based on 92 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/receiver+operator+characteristics+roc+analysis/OpeRATOR+Lyophilized/pmc12672138-17-54-54
Average 93 stars, based on 92 article reviews
receiver operator characteristics roc analysis - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
Significance Assay:Article Title: Exploring of miR-155-5p, miR-181b-5p, and miR-454-3p Expressions in Circulating Cell-Free RNA: Insights from Peripheral Blood of Uveal Malignant Melanoma Patients Article Snippet: .. Fig. 4 STRING analysis for target genes of miR-454-3p (p value: 0.000129) We examined the diagnostic performance of the miR-155-5p, miR-181b-5p, and miR-454-3p molecules as the candidate biomarkers -in other words, the differentiation power of the uveal malignant melanoma patients with the healthy control group using the Diagnostic Assay:Article Title: Exploring of miR-155-5p, miR-181b-5p, and miR-454-3p Expressions in Circulating Cell-Free RNA: Insights from Peripheral Blood of Uveal Malignant Melanoma Patients Article Snippet: .. Fig. 4 STRING analysis for target genes of miR-454-3p (p value: 0.000129) We examined the diagnostic performance of the miR-155-5p, miR-181b-5p, and miR-454-3p molecules as the candidate biomarkers -in other words, the differentiation power of the uveal malignant melanoma patients with the healthy control group using the Control:Article Title: Exploring of miR-155-5p, miR-181b-5p, and miR-454-3p Expressions in Circulating Cell-Free RNA: Insights from Peripheral Blood of Uveal Malignant Melanoma Patients Article Snippet: .. Fig. 4 STRING analysis for target genes of miR-454-3p (p value: 0.000129) We examined the diagnostic performance of the miR-155-5p, miR-181b-5p, and miR-454-3p molecules as the candidate biomarkers -in other words, the differentiation power of the uveal malignant melanoma patients with the healthy control group using the other:Article Title: Choosing in Freedom or Forced to Choose? Introspective Blindness to Psychological Forcing in Stage-Magic Article Snippet: This can be explicitly measured by a Generated:Article Title: A pathway away from measurement‐based patient‐specific QA: A review of contemporary quality assurance for external‐beam radiotherapy sub‐systems Article Snippet: Adamson et al., 2023 , Evaluated SciMoCa for SRS PSQA purposes and presented the commissioning and implementation process. , 99.2% pass rate observed for a 2%/1mm criteria. In comparison to OSL and scintillator measurements in anthropomorphic phantom a –1.9% mean difference was observed. For 10 patient cases agreement between SciMoCa and TPS was observed at –0.8%, –1.3%, and –0.5% for PTV mean dose, D95% and D1%, respectively, which via AAPM TG‐218 methodology corresponded to passing rate action limits of ±5.2%, ±6.4%, and ±6.3% respectively. Beam modelling, validation, and tolerances presented could be used as a benchmark for future SciMoCa users for single isocenter multi target SRS. . .. Kowatsch et al., 2023 , Aimed to develop clinically meaningful tolerance levels for SciMoca. utilizing ROC analysis of results for plans with deliberately introduced errors.190 un‐modified clinical plans generated with the Monaco TPS were assessed along with a further 190 plans for which deliberate dose errors in the range of 1.5%–2.5% had been introduced. Derivative Assay:Article Title: A pathway away from measurement‐based patient‐specific QA: A review of contemporary quality assurance for external‐beam radiotherapy sub‐systems Article Snippet: Adamson et al., 2023 , Evaluated SciMoCa for SRS PSQA purposes and presented the commissioning and implementation process. , 99.2% pass rate observed for a 2%/1mm criteria. In comparison to OSL and scintillator measurements in anthropomorphic phantom a –1.9% mean difference was observed. For 10 patient cases agreement between SciMoCa and TPS was observed at –0.8%, –1.3%, and –0.5% for PTV mean dose, D95% and D1%, respectively, which via AAPM TG‐218 methodology corresponded to passing rate action limits of ±5.2%, ±6.4%, and ±6.3% respectively. Beam modelling, validation, and tolerances presented could be used as a benchmark for future SciMoCa users for single isocenter multi target SRS. . .. Kowatsch et al., 2023 , Aimed to develop clinically meaningful tolerance levels for SciMoca. utilizing ROC analysis of results for plans with deliberately introduced errors.190 un‐modified clinical plans generated with the Monaco TPS were assessed along with a further 190 plans for which deliberate dose errors in the range of 1.5%–2.5% had been introduced. |